Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BHST NASDAQ:MIST NASDAQ:RVPH NASDAQ:ZNTL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$8.18+2.8%$7.74$4.66▼$9.90$130.74M0.6820,915 shs5,931 shsMISTMilestone Pharmaceuticals$1.84+1.7%$1.72$0.63▼$2.75$153.84M0.52983,907 shs824,949 shsRVPHReviva Pharmaceuticals$0.45-2.2%$0.46$0.30▼$4.28$31.30M-0.052.32 million shs1.23 million shsZNTLZentalis Pharmaceuticals$1.69-4.0%$1.44$1.01▼$5.44$126.96M1.71819,845 shs560,361 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences+2.76%-6.30%+10.39%+30.46%+817,999,900.00%MISTMilestone Pharmaceuticals+1.66%+8.24%+26.90%+13.23%+26.90%RVPHReviva Pharmaceuticals-2.24%-16.43%-3.04%-53.61%-55.45%ZNTLZentalis Pharmaceuticals-3.98%-15.08%+22.46%+39.09%-44.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHSTBioHarvest SciencesN/AN/AN/AN/AN/AN/AN/AN/AMISTMilestone Pharmaceuticals1.6672 of 5 stars3.11.00.00.02.62.50.0RVPHReviva Pharmaceuticals2.6046 of 5 stars3.61.00.00.02.33.30.6ZNTLZentalis Pharmaceuticals1.925 of 5 stars3.32.00.00.03.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHSTBioHarvest Sciences 3.00Buy$13.6767.07% UpsideMISTMilestone Pharmaceuticals 2.25Hold$5.00171.74% UpsideRVPHReviva Pharmaceuticals 3.14Buy$5.201,055.56% UpsideZNTLZentalis Pharmaceuticals 2.67Moderate Buy$8.20385.21% UpsideCurrent Analyst Ratings BreakdownLatest RVPH, MIST, ZNTL, and BHST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/18/2025RVPHReviva PharmaceuticalsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $3.008/18/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.008/15/2025RVPHReviva PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/15/2025RVPHReviva PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $2.008/7/2025ZNTLZentalis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/7/2025ZNTLZentalis PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.00 ➝ $5.006/27/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.006/5/2025MISTMilestone PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$5.006/3/2025RVPHReviva PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHSTBioHarvest Sciences$30.19M4.45N/AN/A($0.26) per share-31.46MISTMilestone Pharmaceuticals$1M156.38N/AN/A($0.21) per share-8.76RVPHReviva PharmaceuticalsN/AN/AN/AN/A($0.01) per shareN/AZNTLZentalis Pharmaceuticals$67.43M1.81N/AN/A$3.81 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHSTBioHarvest Sciences-$12.91M-$0.70N/AN/AN/A-39.95%-11,357.84%-39.94%N/AMISTMilestone Pharmaceuticals-$41.52M-$0.84N/AN/AN/AN/A-1,672.29%-83.09%11/11/2025 (Estimated)RVPHReviva Pharmaceuticals-$29.92M-$0.65N/AN/AN/AN/AN/A-259.17%11/13/2025 (Estimated)ZNTLZentalis Pharmaceuticals-$165.84M-$2.26N/AN/AN/AN/A-51.62%-40.28%11/11/2025 (Estimated)Latest RVPH, MIST, ZNTL, and BHST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RVPHReviva Pharmaceuticals-$0.15-$0.12+$0.03-$0.12N/AN/A8/12/2025Q2 2025MISTMilestone Pharmaceuticals-$0.18-$0.20-$0.02-$0.20N/AN/A8/11/2025Q2 2025BHSTBioHarvest Sciences-$0.1075-$0.15-$0.0425-$0.24$8.53 million$8.52 million8/6/2025Q2 2025ZNTLZentalis Pharmaceuticals-$0.56-$0.37+$0.19-$0.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHSTBioHarvest SciencesN/AN/AN/AN/AN/AMISTMilestone PharmaceuticalsN/AN/AN/AN/AN/ARVPHReviva PharmaceuticalsN/AN/AN/AN/AN/AZNTLZentalis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHSTBioHarvest SciencesN/A0.600.36MISTMilestone Pharmaceuticals4.064.974.97RVPHReviva PharmaceuticalsN/A0.900.90ZNTLZentalis PharmaceuticalsN/A7.997.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHSTBioHarvest SciencesN/AMISTMilestone Pharmaceuticals86.18%RVPHReviva Pharmaceuticals63.18%ZNTLZentalis PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipBHSTBioHarvest SciencesN/AMISTMilestone Pharmaceuticals19.50%RVPHReviva Pharmaceuticals27.18%ZNTLZentalis Pharmaceuticals1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHSTBioHarvest SciencesN/A16.43 millionN/AN/AMISTMilestone Pharmaceuticals3084.99 million68.42 millionOptionableRVPHReviva Pharmaceuticals568.00 million49.52 millionOptionableZNTLZentalis Pharmaceuticals16072.14 million70.76 millionOptionableRVPH, MIST, ZNTL, and BHST HeadlinesRecent News About These CompaniesZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 28 at 4:15 PM | globenewswire.comZentalis Pharmaceuticals Announces New Chief Legal OfficerAugust 26, 2025 | msn.comZentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate SecretaryAugust 26, 2025 | globenewswire.comGuggenheim Remains a Buy on Zentalis Pharmaceuticals (ZNTL)August 19, 2025 | theglobeandmail.comZentalis Pharmaceuticals (ZNTL) Gets a Buy from TD CowenAugust 18, 2025 | theglobeandmail.comZentalis (ZNTL) Q2 Loss Narrows 70%August 18, 2025 | theglobeandmail.comLeerink Partnrs Has Pessimistic View of ZNTL Q3 EarningsAugust 11, 2025 | marketbeat.comEquities Analysts Offer Predictions for ZNTL Q3 EarningsAugust 11, 2025 | marketbeat.comHC Wainwright Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to "Strong-Buy"August 10, 2025 | marketbeat.comWall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to HoldAugust 10, 2025 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Releases Earnings ResultsAugust 9, 2025 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Primecap Management Co. CAAugust 9, 2025 | marketbeat.comZentalis price target lowered to $5 from $6 at Wells FargoAugust 8, 2025 | msn.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Cut to $5.00 by Analysts at Wells Fargo & CompanyAugust 8, 2025 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Bought by Federated Hermes Inc.August 7, 2025 | marketbeat.comZentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational ProgressAugust 6, 2025 | globenewswire.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Moderate Buy" by BrokeragesAugust 6, 2025 | marketbeat.comGSA Capital Partners LLP Boosts Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)August 3, 2025 | marketbeat.comZentalis Pharmaceuticals (ZNTL) Projected to Post Quarterly Earnings on FridayAugust 1, 2025 | marketbeat.comDecheng Capital LLC Lowers Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)July 30, 2025 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is favoured by institutional owners who hold 59% of the companyJuly 24, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025Zebra Technologies: Riding the Automation Wave to ProfitsBy Thomas Hughes | August 5, 2025Smaller Industrials Names Seeing Surging Growth: Here's WhyBy Nathan Reiff | August 30, 2025RVPH, MIST, ZNTL, and BHST Company DescriptionsBioHarvest Sciences NASDAQ:BHST$8.18 +0.22 (+2.76%) As of 08/29/2025 03:48 PM EasternBioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Milestone Pharmaceuticals NASDAQ:MIST$1.84 +0.03 (+1.66%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.83 -0.01 (-0.54%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.Reviva Pharmaceuticals NASDAQ:RVPH$0.45 -0.01 (-2.24%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.46 +0.01 (+1.33%) As of 08/29/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.Zentalis Pharmaceuticals NASDAQ:ZNTL$1.69 -0.07 (-3.98%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.74 +0.05 (+2.96%) As of 08/29/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
